<DOC>
	<DOCNO>NCT00833768</DOCNO>
	<brief_summary>Approximately 207 hyperphosphatemic CKD patient dialysis enter study approximately 50 site within approximately 9 European country . The purpose study determine sevelamer carbonate tablet dose three time day ( TID ) safe effective treatment control serum phosphorous level hyperphosphatemic CKD patient dialysis . Total length participation approximately 24 week .</brief_summary>
	<brief_title>A Randomised , Double-Blind , Placebo-Controlled Study Investigate Efficacy Safety Sevelamer Carbonate Tablets Dosed Three Times Day Hyperphosphataemic Chronic Kidney Disease Patients Not Dialysis</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Hyperphosphatemia</mesh_term>
	<mesh_term>Sevelamer</mesh_term>
	<criteria>Serum phosphorus measurement ≥4.6 mg/dL ( ≥1.49 mmol/L ) ≤5.5 mg/dL ( ≤1.76 mmol/L discontinuation current phosphate binder therapy applicable . Active dysphagia swallow disorder predisposition current bowel obstruction , ileus , severe gastrointestinal motility disorder include severe constipation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>